Stockreport

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

Elicio Therapeutics, Inc.  (ELTX) 
PDF BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developin [Read more]